Evidence map›Paper›PMID 39308657›Full record

ArticleActa Cardiologica Sinica2024

Yu-Cheng Shih, Bing-Hsiean Tzeng, Meng-Chieh Tsai, Yuan-Bin Yu, Yu-Chien Shiau, Shan-Ying Wang, Yen-Wen Wu

Abstract read
In one paragraph

Article in Acta Cardiologica Sinica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. 2025 Update Consensus ofActa Cardiologica Sinica · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yu-Cheng ShihDivision of Nuclear Medicine, Department of Radiology.
Bing-Hsiean TzengDivision of Cardiology, Cardiovascular Center.
Meng-Chieh TsaiDivision of Medical Imaging, Department of Radiology.
Yuan-Bin YuDivision of Oncology and Hematology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City.
Yu-Chien ShiauDivision of Nuclear Medicine, Department of Radiology.
Shan-Ying WangDivision of Nuclear Medicine, Department of Radiology.
Yen-Wen WuDivision of Nuclear Medicine, Department of Radiology.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Cardiac amyloidosis (CA) is a type of systemic amyloidosis. Amyloid-targeting positron emission tomography (PET) has shown potential as an imaging method for CA. However, the optimal imaging protocol and role of Methods: Patients with suspected CA who had positive or equivocal results of technetium-99m pyrophosphate (PYP) scintigraphy were enrolled for dynamic and late FBB PET imaging. In addition to visual assessment, a kinetic modeling-based approach including target-to-background ratio (TBR) and myocardial retention fraction (RF) of serial images reconstructed from a 20-min dynamic acquisition, and a late image at 110 min post-injection were performed. We compared FBB PET measures of four typical patients with light chain amyloidosis (AL), wild-type transthyretin amyloidosis (ATTRwt), variant transthyretin amyloidosis (ATTRv), and heart failure, respectively. We also reviewed the literature on the clinical use of amyloid PET in CA. Results: Myocardial tracer retention was only found in the AL patient on the late images. TBR and RF were highest in the AL patient followed by the ATTRwt patient, and lowest in the ATTRv and non-CA patients. Conclusions: FBB PET has potential in the detection and non-invasive subtyping of CA, especially in subjects with equivocal PYP findings or monoclonal gammopathy.

Indexed as

18F-florbetaben (FBB)Heart failureLight-chain cardiac amyloidosis (AL-CA)Positron emission tomography (PET)Transthyretin cardiac amyloidosis (ATTR-CA)

Identifiers

PMID39308657
PMCPMC11413950

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.